The FDA has concluded that the known and potential benefits of the J&J vaccine outweigh its known and potential risks.
The pause was proof that the extensive safety monitoring system is working and was able to detect a very small number of adverse events. This pause allowed the CDC’s Advisory Committee on Immunization Practices to conduct an extensive review of what they ultimately found to be 15 cases, as well as inform providers and clinicians about the potential adverse events and how they can be recognized and treated. On April 13, 2021, after six cases of an extremely rare but severe type of blood clot associated with low platelet counts were reported in women who had received the J&J vaccine, the CDC and FDA paused use of the vaccine. Food and Drug Administration (FDA), and the Illinois Department of Public Health lifted the pause on the use of the Johnson & Johnson/ Janssen (J&J) COVID-19 Vaccine in the United States and Illinois. Centers for Disease Control and Prevention (CDC), the U.S.
0 kommentar(er)
